YCBD NYSE Perfumes, Cosmetics & Other Toilet Preparations Financials FY2016βFY2025
cbdMD, Inc. had $19.2M of revenue in fiscal 2025, down 1.5% on the year before. Over five years, revenue changed β14.5% a year on average.
Last close Β· Oct 23, 2026
$0.36
2.7%Hi! I read cbdMD, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β1.5%
No. Sales fell 1.5% last year.
Does it make a profit?
β10.6%
No. It lost money last year.
Does profit turn into cash?
β8.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days cbdMD, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 20, 2026
Friday Β· in 25 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q3 '26 | After the market closes | 10-Q β |
| May 14, 2026 | Q2 '26 | After the market closes | 10-Q β |
| Feb 17, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Nov 21, 2025 | Q4 '25 | Time not announced | 8-K β |
| Aug 14, 2025 | Q3 '25 | After the market closes | 10-Q β |
| May 15, 2025 | Q2 '25 | After the market closes | 10-Q β |
| Feb 13, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Dec 18, 2024 | Q4 '24 | After the market closes | 10-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· cbdMD, Inc. had $19.2M of revenue in fiscal 2025, down 1.5% on the year before. Over five years, revenue changed β14.5% a year on average. Its operating margin was β11.3%, up 5.7Β pts: of every 100 in sales, about β11 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· cbdMD, Inc. lost $2.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$1.6M in fiscal 2025, β8.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably cbdMD, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $26.4M | $6.7M | $1.8M | $2.5M | $2.3M |
| Debt incl. finance leases | $0.1M | $0.1M | $0.0M | β | β |
| Debt / equity | 0.0x | 0.0x | 0.0x | β | β |
| Current ratio | 5.3x | 3.0x | 1.7x | 0.7x | 2.1x |
| Quick ratio | 4.5x | 2.1x | 0.8x | 0.4x | 1.1x |
| Total assets | $125M | $40.8M | $16.2M | $10.6M | $10.4M |
| Total liabilities | $21.7M | $9.4M | $7.2M | $8.6M | $3.2M |
| Shareholders' equity | $103M | $31.4M | $9.0M | $2.0M | $7.2M |
| Net debt (β = net cash) | β$26.3M | β$6.6M | β$1.8M | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· cbdMD, Inc. passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 4 / 8 | 2 / 8 | 4 / 8 | 4 / 9 | 3 / 9 | 4 / 9 | 4 / 8 | 5 / 8 |
| Accruals ratio | β61.5% | 21.7% | 51.0% | β65.7% | 22.7% | β7.9% | β66.5% | β65.4% | β25.0% | β5.6% |
| Altman Z'' | β28.74 | 0.14 | 17.22 | β1.58 | 1.11 | 3.57 | β19.43 | β41.73 | β59.34 | β53.04 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.0M | $4.5M | $0.5M | $23.7M | $41.9M | $44.5M | $35.4M | $24.2M | $19.5M | $19.2M |
| Net interest income | β | β | $0.0M | $0.1M | $0.0M | β$0.0M | $0.0M | $0.1M | β$0.0M | $0.0M |
| Gross profit | $0.4M | $3.1M | $0.4M | $14.5M | $26.4M | $30.0M | $22.3M | $15.0M | $12.0M | $12.0M |
| Operating income | β$3.9M | β$1.4M | β$1.8M | β$14.8M | β$17.6M | β$19.6M | β$78.3M | β$22.5M | β$3.3M | β$2.2M |
| Interest expense | $0.2M | $0.5M | $0.0M | β | β | β | β | β | β | β |
| Pretax income | β | β | β$1.8M | β$47.8M | $11.3M | β$24.3M | β$70.1M | β$22.9M | β$3.7M | β$2.0M |
| Income tax | $0.0M | $0.0M | $0.0M | β$2.4M | $1.3M | β$0.9M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$3.9M | β$1.4M | $0.1M | β$51.4M | $12.6M | β$23.4M | β$70.1M | β$22.9M | β$3.7M | β$2.0M |
| Net income to common | β$3.4M | β$1.7M | β$0.4M | β$50.4M | $12.2M | β$25.9M | β$74.1M | β$26.9M | β$7.7M | β$4.4M |
| Diluted EPS | β$1.13 | β$0.38 | $0.00 | $0.00 | $0.28 | β$0.47 | β$55.80 | β$13.32 | β$14.29 | β$1.09 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.02B | 0.05B | 0.05B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$2.9M | β$2.3M | β$5.6M | β$15.4M | β$10.7M | β$14.1M | β$15.0M | β$4.3M | β$0.4M | β$1.5M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $1.2M | $1.3M | $0.3M | $0.7M | $0.3M | $0.2M | $0.2M |
| Free cash flow | β$3.0M | β$2.3M | β$5.6M | β$16.6M | β$12.0M | β$14.4M | β$15.7M | β$4.6M | β$0.5M | β$1.6M |
| Depreciation and amortization | $0.0M | $0.1M | $0.2M | $0.3M | $0.7M | $1.0M | $0.9M | $0.4M | $0.5M | $0.4M |
| Stock-based compensation | $0.0M | $0.1M | $0.6M | $2.5M | $1.9M | $1.3M | β | β | β | β |
| Acquisitions | β | β | $0.0M | $0.9M | $0.0M | β | β | β | β | β |
| Dividends paid | β | β | β | $0.0M | $0.4M | $2.6M | β | β | β | β |
| Dividends and buybacks | β | β | β | $0.0M | $0.4M | $2.6M | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.0M | $0.3M | $5.3M | $4.9M | $14.9M | $26.4M | $6.7M | $1.8M | $2.5M | $2.3M |
| Total debt | β | β | β | β | $0.3M | $0.1M | $0.1M | $0.0M | β | β |
| Deposits | β | β | $0.0M | $0.0M | β | β | β | β | β | β |
| Current assets | $1.0M | $3.7M | $11.8M | $15.7M | $23.7M | $36.5M | $16.0M | $8.1M | $6.4M | $6.6M |
| Current liabilities | $1.9M | $1.5M | $1.0M | $3.7M | $7.7M | $6.9M | $5.3M | $4.7M | $8.6M | $3.2M |
| Inventory | $0.6M | $0.6M | $0.1M | $5.2M | $4.9M | $5.6M | $4.8M | $4.2M | $2.5M | $2.9M |
| Property and equipment, net | $0.2M | $0.1M | $0.1M | $1.7M | $3.2M | $2.6M | $0.8M | $0.7M | $0.5M | $0.3M |
| Goodwill | β | β | $0.0M | $54.7M | $54.7M | $56.7M | $0.0M | $0.0M | β | $0.0M |
| Intangible assets | $0.5M | $3.2M | $3.2M | $21.6M | $21.6M | $23.0M | $17.8M | $3.2M | $2.9M | $2.1M |
| Total assets | $1.6M | $7.1M | $15.0M | $94.5M | $111M | $125M | $40.8M | $16.2M | $10.6M | $10.4M |
| Total liabilities | $1.9M | $1.9M | $1.0M | $56.9M | $31.7M | $21.7M | $9.4M | $7.2M | $8.6M | $3.2M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $0.4M | $4.2M | $14.0M | $37.6M | $79.2M | $103M | $31.4M | $9.0M | $2.0M | $7.2M |
| Margins | ||||||||||
| Gross margin | 20.3% | 69.7% | 77.3% | 61.4% | 63.0% | 67.4% | 63.1% | 62.0% | 61.6% | 62.4% |
| Operating margin | β191.4% | β30.4% | β391.4% | β62.6% | β42.0% | β44.1% | β221.1% | β93.1% | β17.0% | β11.3% |
| EBITDA margin | β189.2% | β28.8% | β343.0% | β61.3% | β40.3% | β41.8% | β218.4% | β91.4% | β14.7% | β9.4% |
| Net margin | β191.8% | β31.0% | 13.7% | β217.1% | 30.1% | β52.6% | β198.0% | β95.0% | β19.0% | β10.6% |
| FCF margin | β148.9% | β52.2% | β1,219.1% | β70.1% | β28.6% | β32.5% | β44.2% | β19.0% | β2.8% | β8.5% |
| Net interest share of revenue | β | β | 0.0% | 0.3% | 0.1% | β0.1% | 0.0% | 0.3% | β0.2% | 0.2% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β24.0% | β20.2% | β249.0% | β245.6% | β | β |
| Return on capital employed | 1,385.2% | β24.5% | β12.8% | β16.3% | β17.0% | β16.6% | β220.4% | β195.1% | β168.9% | β29.9% |
| Return on equity | β1,072.2% | β60.6% | 0.7% | β199.0% | 21.6% | β25.7% | β104.2% | β113.4% | β67.3% | β44.4% |
| Return on assets | β240.0% | β31.9% | 0.6% | β93.8% | 12.3% | β19.8% | β84.6% | β80.5% | β27.6% | β19.4% |
| Return on tangible equity | β | β179.0% | β3.8% | β | 425.3% | β110.6% | β545.2% | β463.5% | β | β85.8% |
| Growth | ||||||||||
| Revenue growth | β | 120.3% | β89.7% | 5,051.7% | 77.1% | 6.2% | β20.4% | β31.8% | β19.3% | β1.5% |
| Net income growth | β | β | β | β81,879.5% | β | β285.6% | β | β | β | β |
| EPS growth | β | β | β | β | β | β267.9% | β | β | β | β |
| Share count change | β | 51.8% | 71.3% | 130.8% | 152.5% | 21.6% | β97.6% | 52.3% | β73.3% | 646.2% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.0x | 0.0x | 0.0x | 0.0x | β | β |
| Interest coverage | β25.1x | β2.7x | β1,797.1x | β | β | β | β | β | β | β |
| Current ratio | 0.5x | 2.4x | 12.2x | 4.2x | 3.1x | 5.3x | 3.0x | 1.7x | 0.7x | 2.1x |
| Quick ratio | 0.2x | 2.0x | 12.0x | 2.8x | 2.4x | 4.5x | 2.1x | 0.8x | 0.4x | 1.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 6.3% | 0.2% | 5.1% | 5.1% | 3.2% | 0.8% | 1.9% | 1.2% | 1.0% | 1.0% |
| Stock comp / revenue | 0.6% | 1.3% | 139.3% | 10.4% | 4.5% | 2.9% | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 2.0 | 4.0 | 4.0 | 3.0 | 4.0 | 4.0 | 5.0 |
| Altman Z'' | β28.7 | 0.1 | 17.2 | β1.6 | 1.1 | 3.6 | β19.4 | β41.7 | β59.3 | β53.0 |
| Accruals ratio | β61.5% | 21.7% | 51.0% | β65.7% | 22.7% | β7.9% | β66.5% | β65.4% | β25.0% | β5.6% |
Source: SEC EDGAR XBRL filings (CIK 0001644903). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
